The pharmaceutical industry and healthcare payers have long been looking to agree pricing based on the value treatments bring to the individual patient and society at large, with pricing reflecting different uses (indication pricing) and use in combination with other medicines (combination pricing). This is the next big development following the development of health economics and health technology assessment (HTA) to assess the value of medicines. 

“Real world data” will facilitate rebate agreements specific to combinations of medicines and different uses of the same medicine, allowing net prices to be adjusted to reflect the value of different uses. Such agreements have previously proven difficult to implement in practice, primarily for two reasons: (I) the need to access data while respecting patient data privacy, and (II) scalability and sustainability challenges.

Guardtime’s technology addresses these problems, combining secure multi-party computation (MPC) techniques (where no external actor can see any data used to arrive at an outcome) with Guardtime’s KSI® Blockchain for data integrity and time guarantees, with sequencing proof back to underlying data for later audit (i.e. provable answers to questions with privacy). 

The work focuses on understanding the question of “what medicine is used for what purpose.”The longer-term objective is to enable payers and pharma companies to agree contracts that focus on health outcomes, agreed directly between the parties or through exchanges or brokers.

The project started in the middle of March and will last for four months, finishing with live integration of Guardtime technology at data sources in the Swedish health care system.

For further reading - read our whitepapers:

and visit Guardtime Health webpage